Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
**Flavin mononucleotide (FMN)**, also called riboflavin-5'-phosphate, is a derivative of riboflavin (vitamin B2) produced by phosphorylation via the enzyme flavokinase[4][8]. FMN acts as a **redox-active coenzyme** for a wide variety of oxidoreductase enzymes, participating in key electron transfer steps during metabolic processes such as aerobic respiration and photosynthesis[2][4][6][8]. In mitochondria, FMN serves as the first redox cofactor in respiratory Complex I (NADH:ubiquinone oxidoreductase)[8]. FMN is also a cofactor for biological blue-light photoreceptors. It is found bound to proteins as a non-covalent or covalent prosthetic group, contributing to enzymatic catalysis of both one- and two-electron transfer reactions[4][7]. FMN is not a protein target but an essential **cofactor** and **metabolic intermediate**, not considered a direct therapeutic target, receptor, enzyme, or transporter. It is also used as a food color additive (E101a)[4][3]. --- **Explanation of key fields:** - Flavin mononucleotide is not a protein or a receptor—it is a small molecule coenzyme; thus, while essential in biological function, it is not a therapeutic "target" in the conventional sense. Therefore: - **is_target:** false - **is_incorrect:** true (not a legitimate "target" for typical drug action; likely a misinterpretation or miscategorization) - It has many **aliases** related to its chemical structure or food additive use[3][4]. - It functions as a **cofactor** in numerous biological electron transfer reactions, but does not fall within conventional molecular target **families** like receptor, enzyme, or transporter[2][4][6][8]. - It is central to metabolism and energy production but is not itself a direct marker, therapeutic target, or drug substrate[4][6][8]. - **No approved drugs** are designed to bind or inhibit FMN as a primary target[9]. No biomarker or safety profile information is associated, as it is not used as a target for therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Flavin mononucleotide (FMN).